Target Price | $113.09 |
Price | $114.43 |
Deviation | 1.17% |
Number of Estimates | 23 |
23 Analysts have issued a price target Gilead Sciences 2026 . The average Gilead Sciences target price is $113.09. This is 1.17% lower than the current stock price. The highest price target is $140.00 22.35% , the lowest is $90.00 21.35% . | |
A rating was issued by 33 analysts: 21 Analysts recommend Gilead Sciences to buy, 11 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Gilead Sciences stock has an average upside potential 2026 of 1.17% . Most analysts recommend the Gilead Sciences stock at Purchase. |
23 Analysts have issued a sales forecast Gilead Sciences 2025 . The average Gilead Sciences sales estimate is $28.7b . This is 0.19% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $28.9b 0.54% , the lowest is $28.2b 1.88% .
This results in the following potential growth metrics:
2024 | $28.7b | 6.17% |
---|---|---|
2025 | $28.7b | 0.19% |
2026 | $29.8b | 3.87% |
2027 | $31.1b | 4.53% |
2028 | $32.7b | 5.12% |
2029 | $33.4b | 2.11% |
10 Analysts have issued an Gilead Sciences EBITDA forecast 2025. The average Gilead Sciences EBITDA estimate is $14.3b . This is 6.53% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $16.0b 19.33% , the lowest is $13.0b 3.28% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $13.4b | 7.96% |
---|---|---|
2025 | $14.3b | 6.53% |
2026 | $15.2b | 6.43% |
2027 | $16.4b | 7.92% |
2028 | $18.4b | 11.79% |
2029 | $19.7b | 7.20% |
2024 | 46.74% | 1.69% |
---|---|---|
2025 | 49.89% | 6.74% |
2026 | 51.12% | 2.47% |
2027 | 52.78% | 3.25% |
2028 | 56.13% | 6.35% |
2029 | 58.93% | 4.99% |
14 Gilead Sciences Analysts have issued a net profit forecast 2025. The average Gilead Sciences net profit estimate is $7.7b . This is 1,561.60% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $8.3b 1,694.59% , the lowest is $6.2b 1,251.35% .
This results in the following potential growth metrics and future Net Margins:
2024 | $473m | 91.56% |
---|---|---|
2025 | $7.7b | 1,517.88% |
2026 | $8.6b | 12.62% |
2027 | $9.5b | 9.82% |
2028 | $10.4b | 10.08% |
2029 | $10.9b | 4.40% |
2024 | 1.65% | 92.05% |
---|---|---|
2025 | 26.72% | 1,521.16% |
2026 | 28.97% | 8.42% |
2027 | 30.43% | 5.04% |
2028 | 31.87% | 4.73% |
2029 | 32.58% | 2.23% |
14 Analysts have issued a Gilead Sciences forecast for earnings per share. The average Gilead Sciences <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $6.15 . This is 1,562.16% higher than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $6.64 1,694.59% , the lowest is $5.00 1,251.35% .
This results in the following potential growth metrics and future valuations:
2024 | $0.38 | 91.56% |
---|---|---|
2025 | $6.15 | 1,518.42% |
2026 | $6.92 | 12.52% |
2027 | $7.60 | 9.83% |
2028 | $8.37 | 10.13% |
2029 | $8.74 | 4.42% |
Current | 311.71 | 1,768.76% |
---|---|---|
2025 | 18.61 | 94.03% |
2026 | 16.53 | 11.18% |
2027 | 15.05 | 8.95% |
2028 | 13.67 | 9.17% |
2029 | 13.10 | 4.17% |
Based on analysts' sales estimates for 2025, the Gilead Sciences stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 5.52 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 4.97 .
This results in the following potential growth metrics and future valuations:
Current | 5.51 | 34.72% |
---|---|---|
2025 | 5.52 | 0.12% |
2026 | 5.31 | 3.73% |
2027 | 5.08 | 4.33% |
2028 | 4.83 | 4.87% |
2029 | 4.73 | 2.07% |
Current | 4.96 | 43.44% |
---|---|---|
2025 | 4.97 | 0.19% |
2026 | 4.79 | 3.73% |
2027 | 4.58 | 4.33% |
2028 | 4.35 | 4.87% |
2029 | 4.26 | 2.06% |
Gilead Sciences...
Analyst | Rating | Action | Date |
---|---|---|---|
B of A Securities |
Buy
➜
Buy
|
Unchanged | Mar 05 2025 |
Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Mar 05 2025 |
Oppenheimer |
Outperform
➜
Outperform
|
Unchanged | Mar 04 2025 |
Deutsche Bank |
Hold
➜
Buy
|
Upgrade | Feb 18 2025 |
Goldman Sachs |
Neutral
➜
Neutral
|
Unchanged | Feb 12 2025 |
BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Feb 12 2025 |
Needham |
Hold
➜
Hold
|
Unchanged | Feb 12 2025 |
Analyst Rating | Date |
---|---|
Unchanged
B of A Securities:
Buy
➜
Buy
|
Mar 05 2025 |
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Mar 05 2025 |
Unchanged
Oppenheimer:
Outperform
➜
Outperform
|
Mar 04 2025 |
Upgrade
Deutsche Bank:
Hold
➜
Buy
|
Feb 18 2025 |
Unchanged
Goldman Sachs:
Neutral
➜
Neutral
|
Feb 12 2025 |
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Feb 12 2025 |
Unchanged
Needham:
Hold
➜
Hold
|
Feb 12 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.